Stockscreener 앱 받기
0.00
100.00%
-0.3291
전일 마감가:
$0.3291
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$29.69M
수익:
-
순이익/손실:
$-166.14M
주가수익비율:
0.00
EPS:
-1.92
순현금흐름:
$-139.92M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.3295
52주 변동 폭
$0.00
$1.555
Allakos Inc Stock (ALLK) Company Profile
명칭
Allakos Inc
전화
650-597-5002
주소
825 INDUSTRIAL ROAD, SAN CARLOS, CA
ALLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.00 | 29.69M | 0 | -166.14M | -139.92M | -1.92 |
|
ONC
Beigene Ltd Adr
|
236.12 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.77 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.62 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.80 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-01-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | 재개 | Jefferies | Buy |
| 2023-09-27 | 개시 | JMP Securities | Mkt Outperform |
| 2023-05-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-07 | 개시 | Piper Sandler | Overweight |
| 2022-09-12 | 다운그레이드 | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-12-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-07-15 | 개시 | Cowen | Outperform |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2021-02-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-15 | 개시 | BofA Securities | Buy |
| 2020-12-21 | 개시 | SVB Leerink | Outperform |
| 2020-02-27 | 개시 | Barclays | Underweight |
| 2020-02-04 | 재개 | Goldman | Neutral |
| 2018-08-13 | 개시 | Goldman | Neutral |
| 2018-08-13 | 개시 | Jefferies | Buy |
| 2018-08-13 | 개시 | William Blair | Outperform |
모두보기
Allakos Inc 주식(ALLK)의 최신 뉴스
Allakos stock hits 52-week low at $0.3 amid market challenges - MSN
Allakos completes merger with Concentra Biosciences By Investing.com - Investing.com South Africa
Allakos Completes Merger with Concentra Biosciences - TipRanks
Allakos completes merger with Concentra Biosciences - Investing.com
Allakos Inc.(NasdaqGS: ALLK) dropped from S&P TMI Index - marketscreener.com
Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC - Defense World
Allakos Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
ALLK Shares Experience Decline in Value - knoxdaily.com
Renaissance Technologies LLC Has $1.02 Million Position in Allakos Inc. (NASDAQ:ALLK) - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Checking in on Allakos Inc (ALLK) after recent insiders movement - knoxdaily.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders - PR Newswire
Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million. - marketscreener.com
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share - MarketScreener
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos surges on reverse merger deal with Concentra Biosciences - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com India
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com
Allakos Inc (ALLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
1.61%
자본화:
|
볼륨(24시간):